ANN ARBOR, Mich., Oct. 4, 2007 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced positive interim results from two separate research groups utilizing autologous stem cell products manufactured with the Company’s proprietary Tissue Repair Cell (TRC) Technology platform. The first study reported positive results from the use of Aastrom Vascular Repair Cells (VRCs) in the treatment of chronic diabetic foot wounds associated with critical limb ischemia (CLI). In another presentation, positive results from the use of Aastrom Bone Repair Cells (BRCs) in the treatment of osteonecrosis of the femoral head were presented. Primary investigators from each of these research groups presented data today at the 2nd Congress of the German Society for Stem Cell Research in Wurzburg, Germany.
